Melbourne, Australia; 29 October 2019 – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, today announced the publication of positive data from the first-in-human clinical trial of OPT-302, in patients with neovascular (wet) age-related macular degeneration (wet AMD). The successful trial results were published today in Ophthalmology Retina, […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-10-31 14:39:092019-10-31 14:39:09Pravin U. Dugel, MD: Opthea First-in-Human Clinical Data for OPT-302 in wet AMD Published in Leading Ophthalmic Journal
October 08, 2019 01:15 ET | Source: Novartis International AG In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients[1],[2] Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-10-08 12:13:282019-10-08 12:13:28Pravin U. Dugel, MD: Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Professor Pravin U. Dugel, MD Pravin Dugel, Clinical Professor at the Roski Eye Institute, University of Southern California, USA, provides his expert insight into key data presented at EURETINA 2019 and discusses the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD. Clinical Spotlight Why retinal fluid is important […]
“Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm,” the company said Clinical update and conference presentations “Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa ReNeuron Group plc (AIM: RENE), a global leader in the development […]
American Vision Partners (“AVP”), one of the largest and fastest-growing eye care physician practice management organizations in the nation, announced the completion of a strategic partnership with Retinal Consultants of Arizona (“RCA”), the largest retina provider in the Southwest. This partnership creates the fourth largest retina practice in the nation. Retinal Consultants of Arizona will […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-09-25 17:44:192021-03-25 05:14:16Retinal Consultants of Arizona partners with American Vision Partners
Eric D. Donnenfeld, M.D., an internationally recognized expert and pioneer in refractive, cornea and cataract surgery Ramin Tadayoni, M.D., Ph.D., renowned professor and ophthalmologist in the diagnosis and treatment of retinal diseases, retinovitreal surgery and ophthalmic imaging Lausanne, Switzerland, September 17, 2019 – Oculis S.A., a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments for […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-09-17 03:33:022019-09-17 03:33:02Pravin U. Dugel, MD: Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Board
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME Immediate onset of action – starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149. Prolonged durability […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-09-16 00:14:072019-09-16 00:14:07Pravin U. Dugel, MD: Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME
Watch the Financing Retinal Innovation panel at Ophthalmology Innovation Summit @ ASRS 2019. The panel takes places at OIS@ASRS at the Ritz Carlton in Chicago on July 25, 2019. Participants: Emmett T. Cunningham Jr., MD, Ph.D., MPH, Senior Managing Director – Blackstone Life Sciences Michael Keyoung, MD, Ph.D., Managing Director & Head, North America – […]
September 4, 2019|Steve Lenier CHICAGO – As innovation in the retina space has grown over the past quarter-century, so has the need for capital to finance those activities. One way innovators are meeting that need is by entering into partnerships with ex-US entities, one of many issues explored by a panel session on financing retina […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-09-05 19:25:182019-09-05 19:25:18Pravin U. Dugel MD: As Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For
OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® The primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated a statistically significant vision benefit compared to Lucentis in wet AMD patients at 24 weeks in a trial of 366 patients Intravitreal OPT-302 combination therapy was well tolerated with a safety profile similar to […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-08-07 13:25:532019-08-07 13:25:53Pravin U. Dugel, MD: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
Pravin U. Dugel, MD: Opthea First-in-Human Clinical Data for OPT-302 in wet AMD Published in Leading Ophthalmic Journal
/ Uncategorized /by retinalconsultantsMelbourne, Australia; 29 October 2019 – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, today announced the publication of positive data from the first-in-human clinical trial of OPT-302, in patients with neovascular (wet) age-related macular degeneration (wet AMD). The successful trial results were published today in Ophthalmology Retina, […]
Pravin U. Dugel, MD: Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
/ Uncategorized /by retinalconsultantsOctober 08, 2019 01:15 ET | Source: Novartis International AG In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients[1],[2] Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the […]
Pravin U. Dugel, MD: Touch Ophthalmology Congress Expert Interviews
/ Uncategorized /by retinalconsultantsProfessor Pravin U. Dugel, MD Pravin Dugel, Clinical Professor at the Roski Eye Institute, University of Southern California, USA, provides his expert insight into key data presented at EURETINA 2019 and discusses the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD. Clinical Spotlight Why retinal fluid is important […]
ReNeuron hails “clear signal” from retinitis pigmentosa trials
/ Uncategorized /by retinalconsultants“Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm,” the company said Clinical update and conference presentations “Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa ReNeuron Group plc (AIM: RENE), a global leader in the development […]
Retinal Consultants of Arizona partners with American Vision Partners
/ Media /by retinalconsultantsAmerican Vision Partners (“AVP”), one of the largest and fastest-growing eye care physician practice management organizations in the nation, announced the completion of a strategic partnership with Retinal Consultants of Arizona (“RCA”), the largest retina provider in the Southwest. This partnership creates the fourth largest retina practice in the nation. Retinal Consultants of Arizona will […]
Pravin U. Dugel, MD: Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Board
/ Uncategorized /by retinalconsultantsEric D. Donnenfeld, M.D., an internationally recognized expert and pioneer in refractive, cornea and cataract surgery Ramin Tadayoni, M.D., Ph.D., renowned professor and ophthalmologist in the diagnosis and treatment of retinal diseases, retinovitreal surgery and ophthalmic imaging Lausanne, Switzerland, September 17, 2019 – Oculis S.A., a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments for […]
Pravin U. Dugel, MD: Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME
/ Uncategorized /by retinalconsultantsOxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME Immediate onset of action – starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149. Prolonged durability […]
Pravin U. Dugel MD: Financing Retinal Innovation Panel At Ophthalmology Innovation Summit @ ASRS 2019
/ Uncategorized /by retinalconsultantsWatch the Financing Retinal Innovation panel at Ophthalmology Innovation Summit @ ASRS 2019. The panel takes places at OIS@ASRS at the Ritz Carlton in Chicago on July 25, 2019. Participants: Emmett T. Cunningham Jr., MD, Ph.D., MPH, Senior Managing Director – Blackstone Life Sciences Michael Keyoung, MD, Ph.D., Managing Director & Head, North America – […]
Pravin U. Dugel MD: As Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For
/ Uncategorized /by retinalconsultantsSeptember 4, 2019|Steve Lenier CHICAGO – As innovation in the retina space has grown over the past quarter-century, so has the need for capital to finance those activities. One way innovators are meeting that need is by entering into partnerships with ex-US entities, one of many issues explored by a panel session on financing retina […]
Pravin U. Dugel, MD: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
/ Uncategorized /by retinalconsultantsOPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® The primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated a statistically significant vision benefit compared to Lucentis in wet AMD patients at 24 weeks in a trial of 366 patients Intravitreal OPT-302 combination therapy was well tolerated with a safety profile similar to […]